Peter Greenleaf has extensive experience guiding publicly traded biopharmaceutical companies through corporate strategy, business development, M&A, advancing drug pipelines, commercialization, and board governance. He has served on multiple public and private boards during his career and is currently the Chairman of Pelthos Therapeutics (Nasdaq: PTHS) and a director of Revolo Biotherapeutics, a private biotechnology company.
Mr. Greenleaf served as President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals from 2019 to 2026, where he led the company through the development and commercialization of therapies for autoimmune diseases, including lupus nephritis. Previously, he was CEO and Chairman of Sucampo Pharmaceuticals, overseeing its sale to Mallinckrodt Pharmaceuticals for approximately $1.2 billion. He also served as CEO of Cerecor and Histogenics.
Earlier in his career, Mr. Greenleaf spent several years at MedImmune, AstraZeneca’s biologics subsidiary, where he served as President and led commercial operations, corporate development, and strategy. He also served as President of MedImmune Ventures, overseeing investments in emerging biotechnology, medical device, and diagnostics companies. Before MedImmune, he held commercial leadership positions at Centocor, now part of Johnson & Johnson’s Janssen organization, and Boehringer Mannheim, now part of Roche.
Mr. Greenleaf holds a Master of Business Administration from Saint Joseph’s University, Philadelphia, and a Bachelor of Science from Western Connecticut State University, Danbury, Conn.
